The Benefit of Post-Mastectomy Radiotherapy in YpN0 Patients After Neoadjuvant Chemotherapy According to Molecular Subtypes

Overview

Journal J Breast Cancer

Date 2019 Jul 9

PMID 31281730

Citations 10

Authors

Won Kyung Cho

Won Park

Doo Ho Choi

Yong Bae Kim

Jin Ho Kim

Su Ssan Kim

Kyubo Kim

Jin Hee Kim

Sung-Ja Ahn

Sun Young Lee

Jeongshim Lee

Sang-Won Kim

Jeanny Kwon

Ki Jung Ahn

Affiliations

Soon will be listed here.

Abstract

Purpose: The benefit of post-mastectomy radiation therapy (PMRT) in patients with breast cancer who achieve ypN0 following neoadjuvant chemotherapy (NAC) has not yet been established. This study aimed to identify the role of PMRT in patients who achieve ypN0 according to molecular subtype.

Methods: We identified patients initially suspected with axillary disease who achieved ypN0 following NAC. From 13 institutions of the Korean Radiation Oncology Group between 2005 and 2011, a total of 189 patients were included in the analysis. Effects of PMRT on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) were evaluated for different molecular subtypes.

Results: In all patients, the prognostic effect of PMRT on LRC, DFS, or OS was not significant. Subgroups analysis showed that the effect of PMRT on LRC was different according to molecular subtype ( for interaction = 0.019). PMRT was associated with greater LRC in the luminal subtype ( = 0.046), but not in other subtypes.

Conclusion: In patients who achieve ypN0 following NAC and mastectomy, PMRT shows no additional survival benefits for any molecular subtype.

Citing Articles

Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?.

Tan C, Wang J, Zhong X, Dai Z, Xiang Z, Zeng Y Breast Cancer Res Treat. 2024; 206(1):45-56.

PMID: 38616207 DOI: 10.1007/s10549-024-07249-2.

Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?.

Alamoodi M Eur J Breast Health. 2024; 20(2):81-88.

PMID: 38571693 PMC: 10985578. DOI: 10.4274/ejbh.galenos.2024.2023-12-14.

The Role of Sentinel Lymph Node Biopsy in Breast Cancer Patients Who Become Clinically Node-Negative Following Neo-Adjuvant Chemotherapy: A Literature Review.

Ferrarazzo G, Nieri A, Firpo E, Rattaro A, Mignone A, Guasone F Curr Oncol. 2023; 30(10):8703-8719.

PMID: 37887530 PMC: 10605278. DOI: 10.3390/curroncol30100630.

De-escalating postoperative radiation therapy after primary systemic therapy in cT1-2N1 breast cancer: lesson from the RAPCHEM/BOOG 2010-03 trial.

Banini M, Visani L, Livi L, Meattini I Ann Transl Med. 2023; 11(10):366.

PMID: 37675297 PMC: 10477657. DOI: 10.21037/atm-23-1051.

Temporal Trends and Factors Associated with Receipt of Post-mastectomy Radiation After Neoadjuvant Chemotherapy in Women with cT3 Breast Cancer.

Manik R, Grady C, Elmore L, Fieber J, Freedman G, Jankowitz R Ann Surg Oncol. 2023; 30(11):6506-6515.

PMID: 37460741 PMC: 10818161. DOI: 10.1245/s10434-023-13730-x.

References

Hamy A, Lam G, Laas E, Darrigues L, Balezeau T, Guerin J . Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma. Breast Cancer Res Treat. 2018; 169(2):295-304. DOI: 10.1007/s10549-017-4610-0. View

Jagsi R, Raad R, Goldberg S, Sullivan T, Michaelson J, Powell S . Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005; 62(4):1035-9. DOI: 10.1016/j.ijrobp.2004.12.014. View

Liu Y, Saraf A, Lee S, Zhong X, Hibshoosh H, Kalinsky K . Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2016; 157(3):555-64. PMC: 5337480. DOI: 10.1007/s10549-016-3837-5. View

Le Scodan R, Selz J, Stevens D, Bollet M, De La Lande B, Daveau C . Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2011; 82(1):e1-7. DOI: 10.1016/j.ijrobp.2010.12.054. View

Mamounas E, Anderson S, Dignam J, Bear H, Julian T, Geyer Jr C . Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012; 30(32):3960-6. PMC: 3488269. DOI: 10.1200/JCO.2011.40.8369. View

Rusthoven C, Rabinovitch R, Jones B, Koshy M, Amini A, Yeh N . The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol. 2016; 27(5):818-27. DOI: 10.1093/annonc/mdw046. View

Tseng Y, Uno H, Hughes M, Niland J, Wong Y, Theriault R . Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. Int J Radiat Oncol Biol Phys. 2015; 93(3):622-30. DOI: 10.1016/j.ijrobp.2015.07.006. View

McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M . Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014; 383(9935):2127-35. PMC: 5015598. DOI: 10.1016/S0140-6736(14)60488-8. View

Koh W, Abu-Rustum N, Bean S, Bradley K, Campos S, Cho K . Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16(2):170-199. DOI: 10.6004/jnccn.2018.0006. View

10.

Kyndi M, Sorensen F, Knudsen H, Overgaard M, Nielsen H, Overgaard J . Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26(9):1419-26. DOI: 10.1200/JCO.2007.14.5565. View

11.

Puig C, Hoskin T, Day C, Habermann E, Boughey J . National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study. Ann Surg Oncol. 2016; 24(5):1242-1250. DOI: 10.1245/s10434-016-5733-y. View

12.

Laurberg T, Tramm T, Nielsen T, Alsner J, Nord S, Myhre S . Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. Acta Oncol. 2017; 57(1):38-43. DOI: 10.1080/0284186X.2017.1401735. View

13.

Recht A, Comen E, Fine R, Fleming G, Hardenbergh P, Ho A . Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J Clin Oncol. 2016; 34(36):4431-4442. DOI: 10.1200/JCO.2016.69.1188. View

14.

Abi-Raad R, Boutrus R, Wang R, Niemierko A, MacDonald S, Smith B . Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2011; 81(3):e151-7. PMC: 3722592. DOI: 10.1016/j.ijrobp.2011.01.015. View

15.

Liu J, Mao K, Jiang S, Jiang W, Chen K, Kim B . The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget. 2015; 7(17):24848-59. PMC: 5029747. DOI: 10.18632/oncotarget.6664. View

16.

Ryu Y, Kang S, Cho J, Yoon J, Park M . Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy. Medicine (Baltimore). 2018; 97(30):e11647. PMC: 6078671. DOI: 10.1097/MD.0000000000011647. View

17.

Rong Q, Wang S, Tang Y, Jin J, Song Y, Wang W . [The role of postmastectomy radiotherapy in clinical T1-3N1M0 breast cancer patients with pathological negative lymph nodes after neoadjuvant chemotherapy and mastectomy]. Zhonghua Zhong Liu Za Zhi. 2017; 39(6):445-452. DOI: 10.3760/cma.j.issn.0253-3766.2017.06.009. View

18.

Rastogi K, Sharma S, Gupta S, Agarwal N, Bhaskar S, Jain S . Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation. Radiat Oncol J. 2018; 36(1):71-78. PMC: 5903359. DOI: 10.3857/roj.2017.00381. View

19.

Truong P, Sadek B, Lesperance M, Alexander C, Shenouda M, Raad R . Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?. Int J Radiat Oncol Biol Phys. 2013; 88(1):57-64. DOI: 10.1016/j.ijrobp.2013.09.024. View

20.

Nagar H, Mittendorf E, Strom E, Perkins G, Oh J, Tereffe W . Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011; 81(3):782-7. DOI: 10.1016/j.ijrobp.2010.06.027. View